| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
|
Cancer Chemother Pharmacol
|
2011
|
1.03
|
|
2
|
Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
|
J Clin Pharmacol
|
2010
|
0.93
|
|
3
|
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
|
Br J Clin Pharmacol
|
2011
|
0.92
|
|
4
|
A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
|
Int J Cancer
|
2011
|
0.90
|
|
5
|
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.
|
Cancer Chemother Pharmacol
|
2012
|
0.82
|
|
6
|
Fusion-protein truncation provides new insights into leukemogenesis.
|
Proc Natl Acad Sci U S A
|
2004
|
0.77
|